CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS

Abstract. Thirty-nine patients with a progredient clinical form of chronic multiple sclerosis (MS) were subject to multiple immunization with autologous polyclonal T-cell vaccines. Two years after initiating the vaccine therapy, no evidence for disease progression was noted in 16 patients (41% of to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	G. Seledtsova, I. Ivanova, S. Mamaev, D. Seledtsov, N. Malkova, V. Seledtsov, V. I. Seledtsov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	т-cell vaccination multiple sclerosis cytokines antimyelin antibodies anti-idiotypic antibodies Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/11d716334678400fa1244b5a38eb86b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11d716334678400fa1244b5a38eb86b3
record_format	dspace
spelling	oai:doaj.org-article:11d716334678400fa1244b5a38eb86b32021-11-18T08:03:40ZCLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS1563-06252313-741X10.15789/1563-0625-2012-1-2-103-108https://doaj.org/article/11d716334678400fa1244b5a38eb86b32014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/303https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Thirty-nine patients with a progredient clinical form of chronic multiple sclerosis (MS) were subject to multiple immunization with autologous polyclonal T-cell vaccines. Two years after initiating the vaccine therapy, no evidence for disease progression was noted in 16 patients (41% of total). Neurological improvement was observed in five cases (13%) from the vaccine-treated group. Of 22 control MS patients who did not receive the immunotherapy, only 6 persons (27%) exhibited stabilization of their clinical state. Clinical improvement was not detectable among this group of MS patients. A group of twenty-six MS patients was treated with Rebif, without evidence of disease progression in eleven cases (42%), and distinct neurological improvement noted in one patient (4%) from this group. One year after starting the vaccine therapy, a rise in serum IL-10 was detected in vaccine-treated patients, whereas IL-17 and IL-18 serum levels remained within the initial ranges. A correlation between the serum levels of anti-myelin antibodies and appropriate anti-idiotypic antibodies was revealed in these patients. In general, the results obtained suggest polyclonal T-cell vaccination as a potentially effective treatment approach, both at early and more advanced stages of the disorder.G. SeledtsovaI. IvanovaS. MamaevD. SeledtsovN. MalkovaV. SeledtsovV. I. SeledtsovSPb RAACIarticleт-cell vaccinationmultiple sclerosiscytokinesantimyelin antibodiesanti-idiotypic antibodiesImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 14, Iss 1-2, Pp 103-108 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	т-cell vaccination multiple sclerosis cytokines antimyelin antibodies anti-idiotypic antibodies Immunologic diseases. Allergy RC581-607
spellingShingle	т-cell vaccination multiple sclerosis cytokines antimyelin antibodies anti-idiotypic antibodies Immunologic diseases. Allergy RC581-607 G. Seledtsova I. Ivanova S. Mamaev D. Seledtsov N. Malkova V. Seledtsov V. I. Seledtsov CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
description	Abstract. Thirty-nine patients with a progredient clinical form of chronic multiple sclerosis (MS) were subject to multiple immunization with autologous polyclonal T-cell vaccines. Two years after initiating the vaccine therapy, no evidence for disease progression was noted in 16 patients (41% of total). Neurological improvement was observed in five cases (13%) from the vaccine-treated group. Of 22 control MS patients who did not receive the immunotherapy, only 6 persons (27%) exhibited stabilization of their clinical state. Clinical improvement was not detectable among this group of MS patients. A group of twenty-six MS patients was treated with Rebif, without evidence of disease progression in eleven cases (42%), and distinct neurological improvement noted in one patient (4%) from this group. One year after starting the vaccine therapy, a rise in serum IL-10 was detected in vaccine-treated patients, whereas IL-17 and IL-18 serum levels remained within the initial ranges. A correlation between the serum levels of anti-myelin antibodies and appropriate anti-idiotypic antibodies was revealed in these patients. In general, the results obtained suggest polyclonal T-cell vaccination as a potentially effective treatment approach, both at early and more advanced stages of the disorder.
format	article
author	G. Seledtsova I. Ivanova S. Mamaev D. Seledtsov N. Malkova V. Seledtsov V. I. Seledtsov
author_facet	G. Seledtsova I. Ivanova S. Mamaev D. Seledtsov N. Malkova V. Seledtsov V. I. Seledtsov
author_sort	G. Seledtsova
title	CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
title_short	CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
title_full	CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
title_fullStr	CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
title_full_unstemmed	CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
title_sort	clinical and immunological aspects of t c ell-based vaccine therapy in patients with progredient multiple sclerosis
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/11d716334678400fa1244b5a38eb86b3
work_keys_str_mv	AT gseledtsova clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT iivanova clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT smamaev clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT dseledtsov clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT nmalkova clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT vseledtsov clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT viseledtsov clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis
_version_	1718422525568876544

CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS

Ejemplares similares